Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare
EGFR mutation
H773dup
NSCLC
afatinib
exon 20 insertion
long-term response
uncommon mutation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
08
2020
accepted:
16
11
2020
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
Unlike most other primary epidermal growth factor receptor (
Identifiants
pubmed: 33575211
doi: 10.3389/fonc.2020.593852
pmc: PMC7871906
doi:
Types de publication
Case Reports
Langues
eng
Pagination
593852Informations de copyright
Copyright © 2021 Zöchbauer-Müller, Kaserer, Prosch, Cseh, Solca, Bauer and Müllauer.
Déclaration de conflit d'intérêts
SZM reports advisory council or committee relationship with Boehringer Ingelheim, Roche, MSD, BMS, Takeda, and AstraZeneca, honoraria from Bayer and Pfizer, and grants or funds from MSD. HP reports advisory council or committee relationship with Boehringer Ingelheim, Roche, MSD, and honoraria from Boehringer Ingelheim, Roche, MSD, BMS, and AstraZeneca. AC, FS, and MB report employment with Boehringer Ingelheim. LM reports consulting fees (advisory boards) from Boehringer Ingelheim. The authors declare that this case report received funding for medical writing assistance from Boehringer Ingelheim. The funder was involved in the conception and design, analysis and interpretation of data, knowledge generation from molecular data, the writing and reviewing of this article, the final approval, and the decision to submit it for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Thorac Oncol. 2020 May;15(5):803-815
pubmed: 31931137
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141884
Lung Cancer. 2019 Jan;127:146-152
pubmed: 30642543
J Thorac Dis. 2016 Dec;8(12):E1734-E1738
pubmed: 28149626
J Clin Med. 2020 Apr 07;9(4):
pubmed: 32272775
Lancet Oncol. 2015 Jul;16(7):830-8
pubmed: 26051236
Cancer Res. 2017 May 15;77(10):2712-2721
pubmed: 28363995
Asia Pac J Clin Oncol. 2018 Mar;14 Suppl 1:7-9
pubmed: 29508940
Cancer Biol Ther. 2016;17(3):237-45
pubmed: 26785607
J Thorac Oncol. 2016 Jun;11(6):918-23
pubmed: 26964772
Oncotarget. 2015 Nov 17;6(36):38789-803
pubmed: 26515464
Lung Cancer. 2017 Jul;109:137-144
pubmed: 28577943
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
J Thorac Oncol. 2018 Aug;13(8):1222-1226
pubmed: 29702285
Sci Transl Med. 2013 Dec 18;5(216):216ra177
pubmed: 24353160
Mol Cancer Ther. 2013 Feb;12(2):220-9
pubmed: 23371856
Mol Oncol. 2020 Aug;14(8):1695-1704
pubmed: 32412152
Cancer Sci. 2016 Sep;107(9):1179-86
pubmed: 27323238
Ann Oncol. 2016 Nov;27(11):2103-2110
pubmed: 27601237
Cancer Res. 2007 Dec 15;67(24):11924-32
pubmed: 18089823
Medicine (Baltimore). 2019 Jan;98(1):e13890
pubmed: 30608413
Oncogene. 2008 Aug 7;27(34):4702-11
pubmed: 18408761
J Thorac Oncol. 2018 Dec;13(12):1897-1905
pubmed: 30096481
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
J Thorac Oncol. 2013 Feb;8(2):179-84
pubmed: 23328547
Future Oncol. 2018 Jun;14(15):1477-1486
pubmed: 29376400
Eur J Cardiothorac Surg. 2016 Nov;50(5):909-913
pubmed: 27032467
Future Oncol. 2018 May;14(11):1117-1132
pubmed: 29336166
Onco Targets Ther. 2018 Oct 23;11:7323-7331
pubmed: 30425522